Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)

Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)

Abstract Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) are highly effective in treating rheumatoid arthritis (RA), albeit high drug cost has restricted their use in many countries. As a countermeasure, Norway implemented pharmaceutical tendering as a c...

Full description

Bibliographic Details
Main Authors: Alen Brkic, Andreas P Diamantopoulos, Mari Hoff, Espen Andre Haavardsholm, Bjørg Tilde Svanes Fevang, Lene Kristin Brekke, Liz Loli, Camilla Zettel, Gunnstein Bakland, Pawel Mielnik, Glenn Haugeberg
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Health Services Research
Subjects:
Pharmaceutical tendering
Biosimilars
Biologics
Subcutaneous
Intravenous
Online Access:https://doi.org/10.1186/s12913-023-09975-7

Internet

https://doi.org/10.1186/s12913-023-09975-7

Similar Items